Products
Birinkibart Biosimilar Monoclonal Antibody (CD131) for Research
Cat No.: GMP-Bios-INN-1105
Anti-CSF2RB/CD131/IL3RB/IL5RB therapeutic antibody (Pre-made Birinkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Birinkibart is a human monoclonal antibody targeting the common beta chain of the GM-CSF receptor (CSF2RB/CD131). Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1105-1mg | 1mg | 3090 |
| GMP-Bios-INN-1105-10mg | 10mg | |
| GMP-Bios-INN-1105-100mg | 100mg | |
| GMP-Bios-INN-1105-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Birinkibart biosimilar, Whole mAb, Anti-CSF2RB/CD131/IL3RB/IL5RB Antibody: Anti-IL-3RB/CD131/CSF2RB/Cytokine receptor common subunit beta therapeutic antibody |
| INN Name | Birinkibart |
| Target | CSF2RB/CD131/IL3RB/IL5RB |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
